Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Post by whytestockson Jul 17, 2024 11:32am

33 Views

Post# 36136681

Presenting on the Emerging Growth Conference 73 Day 2 on Jul

Just In: $BIXT Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now | BenzingaMIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emer...BIXT - Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now | Benzinga

<< Previous

Bullboard Posts

Two micro-cap stocks with strong fundamentals